Logo image of FEMY

FEMASYS INC (FEMY) Stock Fundamental Analysis

NASDAQ:FEMY - Nasdaq - US31447E1055 - Common Stock - Currency: USD

1.04  -0.02 (-1.89%)

After market: 1.05 +0.01 (+0.96%)

Fundamental Rating

2

Taking everything into account, FEMY scores 2 out of 10 in our fundamental rating. FEMY was compared to 189 industry peers in the Health Care Equipment & Supplies industry. FEMY may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, FEMY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year FEMY has reported negative net income.
FEMY had a negative operating cash flow in the past year.
In the past 5 years FEMY always reported negative net income.
In the past 5 years FEMY always reported negative operating cash flow.
FEMY Yearly Net Income VS EBIT VS OCF VS FCFFEMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

FEMY has a worse Return On Assets (-159.02%) than 91.01% of its industry peers.
The Return On Equity of FEMY (-1057.44%) is worse than 88.89% of its industry peers.
Industry RankSector Rank
ROA -159.02%
ROE -1057.44%
ROIC N/A
ROA(3y)-89.97%
ROA(5y)-77.42%
ROE(3y)-322.97%
ROE(5y)-238.66%
ROIC(3y)N/A
ROIC(5y)N/A
FEMY Yearly ROA, ROE, ROICFEMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

With a decent Gross Margin value of 66.24%, FEMY is doing good in the industry, outperforming 69.84% of the companies in the same industry.
FEMY's Gross Margin has declined in the last couple of years.
FEMY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y-2.71%
FEMY Yearly Profit, Operating, Gross MarginsFEMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K

0

2. Health

2.1 Basic Checks

FEMY does not have a ROIC to compare to the WACC, probably because it is not profitable.
FEMY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for FEMY has been increased compared to 5 years ago.
FEMY has a worse debt/assets ratio than last year.
FEMY Yearly Shares OutstandingFEMY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
FEMY Yearly Total Debt VS Total AssetsFEMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

FEMY has an Altman-Z score of -17.15. This is a bad value and indicates that FEMY is not financially healthy and even has some risk of bankruptcy.
FEMY has a Altman-Z score of -17.15. This is amonst the worse of the industry: FEMY underperforms 87.83% of its industry peers.
A Debt/Equity ratio of 2.89 is on the high side and indicates that FEMY has dependencies on debt financing.
With a Debt to Equity ratio value of 2.89, FEMY is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.89
Debt/FCF N/A
Altman-Z -17.15
ROIC/WACCN/A
WACC7.79%
FEMY Yearly LT Debt VS Equity VS FCFFEMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

FEMY has a Current Ratio of 0.93. This is a bad value and indicates that FEMY is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.93, FEMY is doing worse than 90.48% of the companies in the same industry.
FEMY has a Quick Ratio of 0.93. This is a bad value and indicates that FEMY is not financially healthy enough and could expect problems in meeting its short term obligations.
FEMY has a worse Quick ratio (0.54) than 92.06% of its industry peers.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.54
FEMY Yearly Current Assets VS Current LiabilitesFEMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

6

3. Growth

3.1 Past

FEMY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.33%.
FEMY shows a strong growth in Revenue. In the last year, the Revenue has grown by 62.05%.
FEMY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.86% yearly.
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.29%
Revenue 1Y (TTM)62.05%
Revenue growth 3Y11.35%
Revenue growth 5Y11.86%
Sales Q2Q%25.86%

3.2 Future

Based on estimates for the next years, FEMY will show a very strong growth in Earnings Per Share. The EPS will grow by 20.95% on average per year.
The Revenue is expected to grow by 117.26% on average over the next years. This is a very strong growth
EPS Next Y30%
EPS Next 2Y27.59%
EPS Next 3Y18.21%
EPS Next 5Y20.95%
Revenue Next Year222.54%
Revenue Next 2Y143.54%
Revenue Next 3Y144.81%
Revenue Next 5Y117.26%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FEMY Yearly Revenue VS EstimatesFEMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
FEMY Yearly EPS VS EstimatesFEMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1

0

4. Valuation

4.1 Price/Earnings Ratio

FEMY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FEMY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FEMY Price Earnings VS Forward Price EarningsFEMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FEMY Per share dataFEMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

FEMY's earnings are expected to grow with 18.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.59%
EPS Next 3Y18.21%

0

5. Dividend

5.1 Amount

FEMY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

FEMASYS INC

NASDAQ:FEMY (5/23/2025, 9:33:17 PM)

After market: 1.05 +0.01 (+0.96%)

1.04

-0.02 (-1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)N/A N/A
Inst Owners10.22%
Inst Owner Change66.93%
Ins Owners7.4%
Ins Owner Change0%
Market Cap28.33M
Analysts82
Price Target8.84 (750%)
Short Float %3.95%
Short Ratio2.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.28%
Min EPS beat(2)-21.89%
Max EPS beat(2)-18.68%
EPS beat(4)0
Avg EPS beat(4)-19.25%
Min EPS beat(4)-21.89%
Max EPS beat(4)-17.65%
EPS beat(8)2
Avg EPS beat(8)-9.65%
EPS beat(12)5
Avg EPS beat(12)-4.41%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-68.03%
Min Revenue beat(2)-70.71%
Max Revenue beat(2)-65.36%
Revenue beat(4)0
Avg Revenue beat(4)-56.25%
Min Revenue beat(4)-72.34%
Max Revenue beat(4)-16.58%
Revenue beat(8)1
Avg Revenue beat(8)-37.83%
Revenue beat(12)1
Avg Revenue beat(12)-30.36%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.05%
EPS NQ rev (1m)-15.55%
EPS NQ rev (3m)-5.05%
EPS NY rev (1m)-19.05%
EPS NY rev (3m)-4.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.67
P/FCF N/A
P/OCF N/A
P/B 14.19
P/tB 14.62
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.06
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -159.02%
ROE -1057.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.24%
FCFM N/A
ROA(3y)-89.97%
ROA(5y)-77.42%
ROE(3y)-322.97%
ROE(5y)-238.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y-2.71%
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 2.89
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.92%
Cap/Sales 50.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.54
Altman-Z -17.15
F-Score4
WACC7.79%
ROIC/WACCN/A
Cap/Depr(3y)62.1%
Cap/Depr(5y)48.65%
Cap/Sales(3y)33.12%
Cap/Sales(5y)25.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.29%
EPS Next Y30%
EPS Next 2Y27.59%
EPS Next 3Y18.21%
EPS Next 5Y20.95%
Revenue 1Y (TTM)62.05%
Revenue growth 3Y11.35%
Revenue growth 5Y11.86%
Sales Q2Q%25.86%
Revenue Next Year222.54%
Revenue Next 2Y143.54%
Revenue Next 3Y144.81%
Revenue Next 5Y117.26%
EBIT growth 1Y-32.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-87.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-84.77%
OCF growth 3YN/A
OCF growth 5YN/A